Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26908232 | 0.76 | KDM4E (0.47) | ALDH1A1KDM4EL3MBTL1HPGDHTT | |
| SCHEMBL29818961 | 0.76 | KDM4E (0.47) | ALDH1A1KDM4EL3MBTL1HPGDHTT | |
| SCHEMBL15409988 | 0.75 | KDM4E (0.37) | ALDH1A1KDM4E | |
| SCHEMBL16560329 | 0.75 | CCR1 (0.40) | ALDH1A1KDM4ECYP2A6 | |
| SCHEMBL16166585 | 0.74 | KDM4E (0.36) | MBOAT4ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL22122693 | 0.74 | KDM4E (0.36) | ALDH1A1KDM4E | |
| SCHEMBL15856196 | 0.74 | GBA1 (0.38) | MBOAT4ALDH1A1KDM4E | |
| SCHEMBL13878887 | 0.74 | HTR2C (0.37) | MBOAT4ALDH1A1KDM4E | |
| SCHEMBL14270233 | 0.73 | LOXL2 (0.47) | ALDH1A1CYP2A6CYP19A1 | |
| SCHEMBL14948664 | 0.71 | HRH3 (0.43) | ALDH1A1KDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269739-B | 1,3, 4-Diazole derivatives as histone deacetylase inhibitors | 奎马特里克斯公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-3956324-B1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX S L (ES) | 2024-02-21 | — | — | EP | disclosed |
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | FUNDACIÓN KERTOR (ES) | 2022-07-07 | — | — | US | disclosed |
| CN-114269739-A | 1,3,4- Oxadiazole derivatives as histone deacetylase inhibitors | 奎马特里克斯公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3956324-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212479-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2020-10-22 | — | — | WO | disclosed |
| EP-1808440-B1 | Non-covalent inhibitors of urokinase and blood vessel formation | WILEX AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| EP-1808440-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | Wilex AG (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1182207-B1 | Non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORP (US) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC6, HDAC1, HDAC3 | MBOAT4 1946/4885ALDH1A1 351/4885KDM4E 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.